Market research
BVXV BiondVax Pharmaceuticals Ltd ADR
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 39
- Dividend yield
- 0.0%
- Beta
- 2.37
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US09073Q1058
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 39
- Dividend yield
- 0.0%
- Beta
- 2.37
About
About BiondVax Pharmaceuticals Ltd ADR
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the BVXV discussion.
5 years, 4 months ago
BiondVax Pharmaceuticals Ltd is currently in a long term downtrend where the price is trading 56.9% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
BiondVax Pharmaceuticals Ltd's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 385.8% to $55M since the same quarter in the previous year.
Finally, its free cash flow grew by 79.4% to $-14M since the same quarter in the previous year.
Based on the above factors, BiondVax Pharmaceuticals Ltd gets an overall score of 3/5.